Valeur202320242025TTMFrais de vente, généraux et administratifs6.14 B6.33 B6.09 B6 BRecherche et développement399 M408 M382 M367 MRésultat d'exploitation2.51 B1.84 B2.41 B2.62 BTotal des produits hors exploitation-72 M-48 M-36 M-30 MCharges d'intérêts, nettes des intérêts capitalisés250 M431 M430 M429 MRésultat hors exploitation, hors charges d'intérêts-308 M-52 M-476 M-469 MRevenus/dépenses exceptionnels-14 M4 M10 M—Résultat avant impôts2.19 B1.42 B2 B2.21 BPart des actionnaires dans le résultat————Impôts526 M385 M529 M591 MIntérêts ne donnant pas le contrôle / intérêts minoritaires————Autres produits/charges après impôts-6 M-69 M-67 M-69 MRésultat net avant activités abandonnées1.66 B1.03 B1.47 B1.62 BActivités abandonnées————Résultat net1.66 B1.03 B1.47 B1.62 BAjustement de dilution————Dividendes privilégiés————Résultat net dilué revenant aux actionnaires ordinaires1.66 B1.03 B1.47 B1.62 BBénéfice par action de base (BPA de base)0.90.540.770.85Bénéfice par action dilué (BPA dilué)0.90.540.760.84Nombre moyen d'actions de base en circulation1.85 B1.92 B1.92 B—Nombre d'actions en circulation après dilution1.85 B1.92 B1.92 B—EBITDA2.35 B1.49 B1.98 B1.82 BEBIT1.2 B860 M1.42 B1.26 BCoût des ventes6.8 B6.5 B6.33 B6.37 BAutres coûts des ventes————Amortissements (flux de trésorerie)627 M622 M557 M564 M
Kenvue Inc. Common Stock
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.